A carregar...
Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
This open‐label, parallel‐group, multicenter study aimed to assess the effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of luseogliflozin. A single 5‐mg dose of luseogliflozin was administered to Japanese patients with type 2 diabetes mellitus in the following groups...
Na minha lista:
| Publicado no: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6220780/ https://ncbi.nlm.nih.gov/pubmed/29693800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.456 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|